|
|
1 Prospect West
Chippenham, Wiltshire SN14 6FH United Kingdom
phone:(44) (0)1249 667 700
fax:(44) (0)1249 667 701
|
|
| Symbol |
VCE |
| Exchange |
SEA |
| Founded |
0 |
| Employees |
|
|
|
| www.vectura.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Inhaled drugs for the treatment of lung diseases and conditions. |
|
| Management |
| Dr Christopher P. Blackwell Chief Executive; Anne Hyland, Chief Financial Officer and Company Secretary; Dr Tim Wright, Commercial Director; Dr Mark Main, Development Director; Dr Martin Shott, Pharmaceutical Operations Director; Stephen Eason, Director of Device Development; Dr Colin Dalton, Director of IP and Corporate Affairs |
| |
|
|
|
|
|
|
|
| Keywords |
| drugs, lungs, pharmaceuticals, pulmonary, diseases, asthma, cystic fibrosis, erectile, ejaculation |
|
|
|
| Description |
|
Vectura develops a range of inhaled drugs for the treatment of lung diseases and conditions. |
|
| Products / Services |
Vectura is developing products for local treatment of pulmonary diseases, such as asthma, COPD and cystic fibrosis, and for the systemic treatment of conditions such as Male Erectile Dysfunction, Premature Ejaculation, and Female Sexual Dysfunction, where the use of the pulmonary route of delivery offers important advantages in terms of speed of onset of action.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
